[
    [
        {
            "time": "2021-02-09",
            "original_text": "犀牛财经晚报：拜腾回应上市传闻博泰与上汽通用五菱举报腾讯垄断",
            "features": {
                "keywords": [
                    "拜腾",
                    "上市传闻",
                    "博泰",
                    "上汽通用五菱",
                    "腾讯",
                    "垄断"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "汽车",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "犀牛财经晚报：拜腾回应上市传闻博泰与上汽通用五菱举报腾讯垄断",
                "Correlation": 2,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "赴港上市贝达药业单品独大难题何解",
            "features": {
                "keywords": [
                    "贝达药业",
                    "赴港上市",
                    "单品独大",
                    "难题"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "赴港上市贝达药业单品独大难题何解",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "A股共发生146宗大宗交易成交40.76亿元（2月9日）",
            "features": {
                "keywords": [
                    "A股",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "市场整体"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股共发生146宗大宗交易成交40.76亿元（2月9日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "贝达药业现3笔大宗交易 共成交12,200.75万元",
            "features": {
                "keywords": [
                    "贝达药业",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业现3笔大宗交易 共成交12,200.75万元",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "贝达药业今日大宗交易成交92.50万股，成交价131.9元折价5.77%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "大宗交易",
                    "折价"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业今日大宗交易成交92.50万股，成交价131.9元折价5.77%",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-08",
            "original_text": "贝达药业(300558.SZ)向香港联交所提交境外上市外资股(H股)上市申请",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "上市申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)向香港联交所提交境外上市外资股(H股)上市申请",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "贝达药业：向香港联交所递交H股上市申请并刊发申请资料",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "上市申请",
                    "申请资料"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：向香港联交所递交H股上市申请并刊发申请资料",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]